Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 for type 2 diabetes: a systematic review and meta-analysis of phase 2 randomized controlled trials
Archives of Endocrinology and Metabolism · 2023
DOI: 10.20945/2359-3997000000614 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Archives of Endocrinology and Metabolism, 2023. Verfasst von Rodrigo Ribeiro E Silva und 4 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Medicina, Universidade da Região de Joinville, Joinville, SC, Brasil, rodrigoribeiroesilva@gmail.com. Hauptthemen laut MEDLINE: Blood Glucose, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
Insulin Icodec is a novel basal insulin analogue designed for once-weekly administration, therefore might propitiate reduction in the frequency of injections and facilitate treatment adherence. This study aimed to determine the glycemic control and safety profile of Insulin Icodec, compared with Glargine U100 in patients with diabetes mellitus type 2. Materials and methods: We performed a systematic review and meta-analysis of randomized controlled trials (RCT) data comparing Once-Weekly Insulin Icodec and Once-Daily Insulin Glargine U100 in patients with type 2 diabetes mellitus. PubMed, Embase, and Cochrane databases were searched for trials published up to May 14, 2022. Data were extracted from published reports and quality assessment was performed per Cochrane recommendations.
Results
Three studies were included comprising 453 patients, 230 (50.77%) using Once-Weekly Insulin Icodec and 223 (49.22%) using Once-Daily Insulin Glargine U100. In the pooled data, Glycated Hemoglobin (MD -0.20% CI -0.33 to -0.07%; P=0.002) change from baseline demonstrated a significantly higher reduction in the Icodec group. Time with Glucose in Range (MD 6.60% CI 3.63 to 9.57%; P < 0.0001) and Insulin Dose Difference (MD 0.97UI CI 0.76 to 1.18UI; P < 0.0001) were higher in the Icodec group. There was no significant difference in fasting plasma glucose, body weight change, hypoglycemia or any adverse event evaluated.
Conclusions
Once-Weekly Insulin Icodec was associated with a small reduction in Glycated Hemoglobin, as well as higher Time with Glucose in Range, with similar hypoglycemic adverse events, when compared with Once-Daily Insulin Glargine U100.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Medicina, Universidade da Região de Joinville, Joinville, SC, Brasil, rodrigoribeiroesilva@gmail.com.
- Departamento de Medicina, Universidade da Região de Joinville, Joinville, SC, Brasil.
Zitieren
APA
Ribeiro E Silva, R., de Miranda Gauza, M., Guisso, M. E. S., da Silva, J. O. N., & Kohara, S. K. (2023). Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 for type 2 diabetes: a systematic review and meta-analysis of phase 2 randomized controlled trials. Archives of Endocrinology and Metabolism. https://doi.org/10.20945/2359-3997000000614
Vancouver
Ribeiro E Silva R, de Miranda Gauza M, Guisso MES, da Silva JON, Kohara SK. Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 for type 2 diabetes: a systematic review and meta-analysis of phase 2 randomized controlled trials. Archives of Endocrinology and Metabolism. 2023. doi:10.20945/2359-3997000000614
BibTeX
@article{RibeiroESilva2023,
author = {Ribeiro E Silva, Rodrigo and de Miranda Gauza, Mateus and Guisso, Maria Eduarda Schramm and da Silva, Júlia Opolski Nunes and Kohara, Suely Keiko},
title = {Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 for type 2 diabetes: a systematic review and meta-analysis of phase 2 randomized controlled trials},
journal = {Archives of Endocrinology and Metabolism},
year = {2023},
doi = {10.20945/2359-3997000000614}
}
EUVIMED